ID: ALA5208935

Max Phase: Preclinical

Molecular Formula: C19H16F2N6O4S

Molecular Weight: 462.44

Representations

Canonical SMILES:  Cc1cnc(Nc2cccc(S(N)(=O)=O)c2)nc1Nc1ccc2c(c1)NC(=O)C(F)(F)O2

Standard InChI:  InChI=1S/C19H16F2N6O4S/c1-10-9-23-18(25-11-3-2-4-13(7-11)32(22,29)30)27-16(10)24-12-5-6-15-14(8-12)26-17(28)19(20,21)31-15/h2-9H,1H3,(H,26,28)(H2,22,29,30)(H2,23,24,25,27)

Standard InChI Key:  HVLJIZBQOBSBKA-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type:

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 462.44

Molecular Weight (Monoisotopic): 462.0922

AlogP: 2.84

#Rotatable Bonds: 5

Polar Surface Area: 148.33

Molecular Species: NEUTRAL

HBA: 8

HBD: 4

#RO5 Violations: 0

HBA (Lipinski): 10

HBD (Lipinski): 5

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 9.76

CX Basic pKa: 4.25

CX LogP: 3.26

CX LogD: 3.25

Aromatic Rings: 3

Heavy Atoms: 32

QED Weighted: 0.45

Np Likeness Score: -1.34

References

1. Chen Y, Li H, Yen R, Heckrodt TJ, McMurtrie D, Singh R, Taylor V, Masuda ES, Park G, Payan DG..  (2022)  Optimization of Pyrimidine Compounds as Potent JAK1 Inhibitors and the Discovery of R507 as a Clinical Candidate.,  13  (11.0): [PMID:36385926] [10.1021/acsmedchemlett.2c00411]

Source

Source(1):

• Scientific Literature